3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
7
Ureteral Neoplasms
3
Muscle Invasive Bladder Urothelial Carcinoma
2
Carcinoma, Renal Cell
2
Advanced Bladder Cancer
2
Urogenital Neoplasms
1
Urachal adenocarcinoma
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Peripheral Nervous System Diseases
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Melanoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Interventions
Acupuncture Therapy
10
Exercise
6
Cryotherapy
6
Paclitaxel
5
Glutamine
4
Surveys and Questionnaires
3
Duloxetine Hydrochloride
3
Dexamethasone
3
Bortezomib
3
Acetylcysteine
3
Thioctic Acid
2
Tablets
2
Sodium Chloride
2
Saline Solution
2
Physical Therapy Modalities
2
Low-Level Light Therapy
2
Fish Oils
2
Fatty Acids, Omega-3
2
ziconotide
1
pembrolizumab
1
nicotinamide-beta-riboside
1
glutamic acid diethyl ester
1
enfortumab vedotin
1
Yoga
1
XELOX
1
Vitamin D
1
Vitamin B Complex
1
Vitamin B 6
1
Vitamin B 12
1
Ultrasonic Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Peripheral Nervous System Diseases
×
enfortumab vedotin
×
Clear all
NCT07629700
2026-06-05
ENDEAVOR
University of Florence
Phase NA
Not yet recruiting
40 enrolled